|
How the loss of Dopamine and Dopamine-Restoring Medicines Affect Movement Performance Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on How the loss of Dopamine and Dopamine-Restoring Medicines Affect Movement Performance conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. How the loss of Dopamine and Dopamine-Restoring Medicines Affect Movement Performance Clinical research trials and How the loss of Dopamine and Dopamine-Restoring Medicines Affect Movement Performance medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including How the loss of Dopamine and Dopamine-Restoring Medicines Affect Movement Performance. How the loss of Dopamine and Dopamine-Restoring Medicines Affect Movement Performance Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a How the loss of Dopamine and Dopamine-Restoring Medicines Affect Movement Performance clinical trial. Participants oftentimes recieve the finest healthcare available for their How the loss of Dopamine and Dopamine-Restoring Medicines Affect Movement Performance condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "H" Clinical Trials Conditions > How the loss of Dopamine and Dopamine-Restoring Medicines Affect Movement Performance  How the loss of Dopamine and Dopamine-Restoring Medicines Affect Movement Performance
How the loss of Dopamine and Dopamine-Restoring Medicines Affect Movement Performance
For Condition: Parkinson Disease
Status: Recruiting
Sponsor(s): National Institute of Neurological Disorders and Stroke (NINDS) ,
Synopsis: This study has two purposes: 1) to understand the effect of a decline of dopamine in the brain during normal aging and in patients with Parkinson's disease, and 2) to investigate how medicines used to treat Parkinson's disease improve movement performance in patients. Patients with Parkinson's disease have difficulty performing precise finger movements, mainly because of a dramatic decrease of a substance called dopamine in parts of the brain. Medicines such as levodopa, which help restore dopamine levels, can greatly improve function; however, little is known about how these drugs work. In normal aging, dopamine decreases slightly in certain parts of the brain, but the importance of this decline is poorly understood. This study may provide new information about Parkinson's disease and normal aging that might lead to better treatment strategies. Patients with mild to moderate Parkinson's disease and healthy volunteers 21 years of age and older may be eligible for this study. All participants must be right-handed. All candidates will be screened with a medical history and physical and neurological examinations, including memory tests and mood examination. Brain function will be studied using functional magnetic resonance imaging (fMRI) study and positron emission tomography (PET). Participants may be asked to stop using medications that can affect the central nervous system, such as sleeping pills or drugs for depression or anxiety, for 1 week before each study visit. Patients with Parkinson's disease may also be asked to stop using antiparkinsonian medications at least 12 hours before each visit. In addition, all participants will be asked to abstain from alcoholic beverages at least 24 hours before the fMRI and PET scans, and from nicotine and caffeine for at least 12 hours before the scans. Participants will have fMRI, which uses a strong magnetic field and radio waves to create images of the brain. The subject lies on a table in a tunnel-like cylinder (the scanner) for 1 to 2 hours, lying still for 5 to 15 minutes at a time. He or she can communicate with the technician or researcher at all times during the test through an intercom system. Scans will be done while the subject is at rest and while he or she is performing finger movements. The movements involve pushing five buttons on a box-each button every 3 seconds on average in a specific order. Patients with Parkinson's disease will be studied off- and then on- medications that restore the levels of levodopa in the brain. Some participants may be asked to undergo a PET scan on a separate visit. A PET scanner is a doughnut-shaped machine similar in appearance to a CT (computed tomography) scanner. PET scans detect radioactivity used to provide information on brain activity. Before the test begins, subjects are given a dose of carbidopa-a medicine that increases the amount of levodopa in the brain. A catheter (thin, plastic tube) is then inserted into an arm or wrist vein, and a radioactive form of levodopa called 18Fluorodopa is injected through the catheter. A moldable plastic mask with large openings for eyes, nose, and mouth is placed on the face to help keep the head still during scanning. The total scan time is 2 hours or less.
Details: In the central nervous system, short-term plasticity can be defined as a change in connection strength following presynaptic inputs. Dopamine, which belongs to the class of neuromodulatory neurotransmitters, is believed to play a role in short-term plasticity. [18F]dopa positron emission tomography (PET) studies have shown a progressive impairment of the presynaptic DAergic function in both healthy elderly subjects (HES) and patients with Parkinson's disease (PD). Both PD and HES are characterized by a progressive decline of performance on some motor tasks and changes in activity in brain areas involved in motor control (including motor control by cognitive functions) as shown by functional imaging studies. However, little is known about the exact neurobiological mechanisms linking DAergic function, brain activity and motor (and cognitive) performances in PD and HES. In the present study, we hypothesize that impaired performance on some motor tasks in those subject groups is related to a dysfunction of task-specific functional connections between areas participating in motor control and that those abnormalities in functional connections might be related, at least in part, to a presynaptic dysfunction of the mesencephalic DAergic system. Strength of functional connections can be measured in vivo in humans using functional imaging and appropriate analysis methods. We will measure cerebral activity in baseline condition and during the execution of sequential finger movements using perfusion functional magnetic resonance imaging (fMRI) in three subject groups: PD patients, healthy elderly and young subjects. Brain activity in patients with PD will be studied off- and then on- medication. Imaging data will be compared in terms of both regional activity and effective connectivity using the statistical parametric mapping (SPM) software. fMRI data will also be compared to images of [18F]dopa uptake obtained using PET in PD patients and healthy elderly subjects. Those experiments should lead to better understand the (patho)physiology of the mesencephalic DAergic system in human motor control and may lead to better treatment strategies in Parkinson's disease.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: We will only include PD patients with a stable clinical response to levodopa and DAergic agents. Patients will always be asked to stop using antiparkinsonian medications prior to each visit: 12 hours for standard release levodopa, 24 hours for controlled release levodopa and dopamine receptor agonists (excepting cabergoline), and 4 days for cabergoline. They will also be asked to stop other medications that can influence the central nervous system for one week prior to each visit. We will only recruit patients with early or mild-to-moderate PD (score on Hoehn & Yahr scale 148 less than 3). To obtain a homogeneous group, the PD cohort will comprise only non-demented, non-depressed, with parkinsonian symptoms and signs primarily akineto-rigid. If resting tremor is present, only patients with mild or moderate tremor (UPDRS tremor ratings 1 or 2 in the right upper limb) will be included in the study. Our group of healthy volunteers will include the following age range: 21-30 years, 31-40 years, 41-50 years, 51-60 years, 61-70 years, and 70 years and over. Subjects of age 35 or younger will not be included in the PET study. Controls will be asked to stop any medications that can influence the central nervous system for one week prior to examination. Research subjects may be male or female. They must be right-handed. Pregnant women will not participate in the study. Research subjects will be asked to refrain from caffeine and nicotine for at least 12 hours and to abstain from alcohol at least 24 hours before the fMRI and the PET studies. EXCLUSION CRITERIA: The subjects belonging to one of the following groups will be excluded from the study: Subjects with a familial history of PD. Patients with a marked resting tremor (score at the UPDRS scale above 3 in the right upper limb). Patients with a score at Hoehn & Yahr scale equal or above 3. Patients with progressive neurological disorders other than PD. Subjects with cognitive impairment (i.e., score on Mattis scale below 123/144). Subjects with significant mood disturbances (i.e., score on BDI scale above 10). Subjects with abnormal MRI findings at visual inspection (prominent normal variants such as mega cisterna or cavum septum pellucidum, signs of severe cortical or subcortical atrophy, brain tumors, vascular diseases, trauma or AVMs). Subjects with a history of significant medical disorders, or requiring chronic treatment with other drugs that cannot be stopped. Subjects with prior exposure to neuroleptic agents or drug use. Subjects with significant past and present history of hypertension, cardiovascular disease and diabetes mellitus. Subjects with severe orthopedic or rheumatologic pathology of the right upper limb. Subjects with past or present neuropsychiatric illness, head trauma with loss of consciousness, epilepsy, cerebro-vascular disease, past and present history of alcohol or substance abuse, including cigarettes, medical conditions that may alter cerebral functioning Subjects with cancer. Subjects with positive urine toxicology. Subjects who have pacemakers, aneurysm clips (metal clips on the wall of a large artery), metallic prostheses (including heart valves and cochlear implants) or shrapnel fragments. Subjects not capable of giving an informed consent. Subjects with a positive pregnancy test. Subjects with pre-existing eyes condition. Children will be excluded from the study.
Total Enrollment: 88
Location and Contact Information:
National Institute of Neurological Disorders and Stroke (NINDS) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 020216; 02-N-0216
Study Start Date: June 19, 2002
Record last reviewed: May 6, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00040196
Other Parkinson Disease Studies:
1. Randomized Study of Fetal Neurotransplantation for the Treatment of Parkinson's Disease
2. Study of LY300164 for the Treatment of Parkinson's Disease
3. The Role of Dopamine in Motor Learning in Healthy Subjects and Patients with Parkinson's Disease
4. Study of Clozapine for the Treatment of Psychosis in Patients with Idiopathic Parkinson's Disease
5. Studying Automatic Movements in Patients with Parkinson's Disease
Related Studies:
Other Parkinson Disease Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
How the loss of Dopamine and Dopamine-Restoring Medicines Affect Movement Performance
|
|
|
|
|
|
|
|
